Shareholder Information

The information on this page was last updated on 31 March 2020.
As at 31 March 2020, the number of shares in issue was 59,416,134.

Significant Shareholdings

Shareholder Number Ordinary Shares %
Christopher Mills 9,199,568 15.48%
Icahn School of Medicine at Mount Sinai 8,853,426 14.90%
James McCullough 2,870,110 4.83%
Lombard Odier & Co Ltd 2,869,334 4.83%
EKF Diagnostics Holdings Plc 2,677,981 4.51%
Canaccord Genuity Wealth Management 2,487,965 4.19%
Polar Capital, LLP 1,949,664 3.28%
O. James Sterling 1,902,640 3.20%
Schroders 1,882,283 3.17%
Legal & General Investment Management 1,805,283 3.04%

Director Shareholdings

Director Number Ordinary Shares %
Christopher Mills 9,199,568 15.48%
James McCullough 2,870,110 4.83%
Julian Baines 1,231,236 2.07%
Richard Evans 706,322 1.19%
Fergus Fleming 584,481 0.98%
Barbara Murphy 150,800 0.25%

Shares not in public hands

As at 31 March 2020 the percentage of AIM securities not in public hands was 55.53%. The securities not in public hands include all significant shareholders, the directors and senior management who are classed as persons discharging managerial responsibilities. There are no shares held in treasury.

Rights of shareholders

The rights of shareholders are governed by UK law.

Restrictions in transfer of ordinary shares

There are no restrictions on the transfer of the company’s ordinary shares.

UK City Code on Takeover and Mergers

The Company is subject to the provisions of the City Code on Takeover and Mergers.

Other exchanges and trading platforms

All of the Company's shares are traded on AIM, a market of London Stock Exchange plc, and American Depositary Shares representing the Company’s ordinary shares are listed on the Nasdaq Global Market. The Company's shares are not traded on any other exchange or trading platform.

The Company is subject to the UK City Code on Takeovers and Mergers.